Merck Januvia Is First DPP-4 Inhibitor To Reach FDA
Firm says the oral DPP-4 inhibitor has a mid-October user fee date for a type 2 diabetes indication.
Firm says the oral DPP-4 inhibitor has a mid-October user fee date for a type 2 diabetes indication.